Business Context and Reporting Period
Company: Prothena Corporation plc (PRTA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2021
Reporting Period: Event date of May 28, 2021
Prothena Corporation plc, an Ireland-domiciled biopharmaceutical company, entered into an Equity Distribution Agreement on May 28, 2021, to facilitate the sale of its ordinary shares.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain periodic financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
- Proposed Offering Size: Up to $100.0 million aggregate offering price.
- Commission Rate: Up to 3.0% of aggregate gross proceeds paid to agents.
- Security Type: Ordinary Shares, par value $0.01 per share.
Material Changes
The material change reported is the execution of an "at-the-market" (ATM) equity distribution agreement. This establishes a mechanism for the Company to sell shares from time to time through designated agents, rather than a single block offering. The filing does not report changes to historical financial performance.
Guidance, Outlook, and Risks
Management Commentary: The Company may instruct agents not to sell shares if sales cannot be effected at or above a designated price. The Company is not obligated to make any sales under the agreement.
Termination Conditions: The offering will terminate upon the earlier of the sale of all shares subject to the agreement or the termination of the agreement by the agents or the Company.
Risks and Contingencies:
- Actual results may differ from predictions due to market conditions.
- Sales are subject to pre-sale conditions under the Distribution Agreement.
- Forward-looking statements regarding the ability to raise funds involve inherent uncertainties.
Investor Verification Checklist
- Verify the current market price of PRTA ordinary shares to assess the potential dilution impact of the $100 million ATM facility.
- Review the full text of the Distribution Agreement (Exhibit 1.1) for specific pricing floors or volume limitations not detailed in the summary.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to understand the necessity of this capital raise.